Search clinical trials for: Dopamine Agonists

Total 16874 results

Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder

Major Depressive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy

Major Depressive Disorder (MDD)

United States
Cairo University

Completed

Midodrine for Prophylaxis Against Post Spinal Hypotension in Elderly Population

Hypotension | Spinal Anesthesia | Elderly

Egypt
Centre for Addiction and Mental Health
Janssen Inc.

Recruiting

Risk of Breakthrough Symptoms With Long-Acting Injectable Medications

Schizophrenia | Schizophrenia Relapse

Canada
University of California, Los Angeles
Alkermes, Inc.

Terminated

Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode (APPRAISE)

Schizophrenia | Schizophreniform Disorder | Schizoaffective Disorder, Depressive Type

United States
Future University in Egypt

Completed

Bioequivalence Study of Aripiprazole in Healthy Adult Subjects Under Fasting Condition

Healthy Subjects

Egypt
Alkermes, Inc.

Completed

A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia

Schizophrenia

United States
University of British Columbia
Bristol-Myers Squibb

Completed

Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI (CALM)

Psychotic Disorders | Bipolar Disorder | Metabolic Syndrome X

Canada
Otsuka Beijing Research Institute

Completed

The Pharmacokinetics, and Safety of Brexpiprazole Tablets in Chinese Healthy Subjects

Healthy

China
Otsuka Pharmaceutical Co., Ltd.

Completed

Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type

Agitation Associated With Dementia of the Alzheimer's Type

Japan
Otsuka Pharmaceutical Development & Commercialization...
Quintiles, Inc.

Completed

Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia (EQUATOR)

Acute Schizophrenia

United States, Malaysia, Serbia, Ukraine, Romania, Puerto Rico, Colombia, Turkey
Azienda Ospedaliera Cardinale G. Panico

Terminated

Possible Use of Rotigotine in Subjects 70 Years and Older With Late Onset of Disease (PARROT)

Parkinson's Disease

Italy
UCB Pharma

Completed

A Trial To Assess Switching From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson's Disease

Parkinson's Disease

United States
UCB Pharma

Completed

Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS) (RESTORE)

Restless Legs Syndrome

United States
UCB Pharma

Completed

Placebo-controlled Study in Patients With Parkinson's Disease to Evaluate the Effect of Rotigotine on Non-motor Symptoms

Idiopathic Parkinson's Disease

Germany, Austria, Belgium, Bulgaria, Czech Republic, France, Hungary, Italy, Romania, Slovakia, Spain, Switzerland
Otsuka Pharmaceutical Co., Ltd.

Completed

A Placebo-Controlled Study for SPM 962 in Restless Legs Syndrome (RLS) Patients

Idiopathic Restless Legs Syndrome

Japan
Axxonis Pharma AG

Completed

Continuous Application of Lisuride in Parkinson's Disease by Subcutaneous Infusion

Parkinson's Disease

Germany
Dr. Albert Kar-Kin Chung
Otsuka Pharmaceutical Co., Ltd.

Recruiting

Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive Disorders (ReSD)

Depression | Psychosis

Hong Kong
Otsuka Pharmaceutical, Inc., Philippines

Recruiting

"Brexpiprazole (Rexulti™) Safety and Efficacy Among Filipino Patients (RAISE) - A Post Marketing Surveillance Program" (RAISE)

Schizophrenia | Major Depressive Disorder

Philippines
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

Alzheimer's Disease

United States
H. Lundbeck A/S
Otsuka Pharmaceutical Co., Ltd.

Completed

Brexpiprazole in Patients With Schizophrenia

Schizophrenia

Serbia, Estonia, United States, Poland, Romania, Russian Federation, Slovakia, Ukraine
UCB Pharma

Completed

Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's Disease Patients

IDIOPATHIC PARKINSON'S DISEASE

China
Larry J. Siever
New York State Psychiatric Institute

Unknown

Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder (SPD)

Schizotypal Personality Disorder | Cognitive Impairments

United States
Shanghai Mental Health Center
Shanghai Jiao Tong University School of Medicine

Not yet recruiting

Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building

Schizophrenia

China
Deborah Yurgelun-Todd
Otsuka America Pharmaceutical

Completed

Study of the Impact of Aripiprazole (Abilify®) Once Monthly Versus Standard of Care Oral Antipsychotic Medications on Changes in Brain Structure and Metabolism

Schizophrenia

United States
Otsuka Beijing Research Institute

Completed

Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette's Syndrome

Tourette Syndrome

China
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder

Bipolar Disorder Mania

Italy, Poland, Russian Federation, Turkey, South Africa, Austria, Hungary, France, Spain, Czech Republic, Germany, Greece, Romania
Chimei Medical Center

Completed

Compare the Efficacy and Tolerability of the Combination of Aripiprazole and Selective Serotonin Reuptake Inhibitors (SSRIs) Used in Major Depression

Major Depressive Disorder

Taiwan
Korea Otsuka Pharmaceutical Co., Ltd.

Recruiting

A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression (APOLLO)

Depression, Bipolar

Korea, Republic of
Otsuka Pharmaceutical Co., Ltd.

Completed

Bioequivalence Between Single Administration of ASC-01 (Aripiprazole/Sertraline Combination Drug) and Concomitant Single Administration of Aripiprazole and Sertraline, and Food Effect on Pharmacokinetics of ASC-01 in Healthy Male Adults

Healthy Male Adults

Japan
UMC Utrecht

Completed

European Long-acting Antipsychotics in Schizophrenia Trial (EULAST)

Schizophrenia

Netherlands, Norway, Austria, Belgium, Bulgaria, Czechia, Denmark, Germany, Greece, Hungary, Israel, Italy, Poland, Romania, Spain, United Kingdom
Northwell Health

Terminated

1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain

High Risk MC4R Genotype | Low Risk MC4R Genotype | One Week or Less Antipsychotic Lifetime Exposure

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.

Schizophrenia | Schizoaffective Disorder

United States
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

Abilify in Bipolar Disorder for 24 Weeks Treatment Effectiveness (SMART-M)

Bipolar Disorder

Korea, Republic of
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

Abilify in Bipolar Disorder for 6 Weeks Treatment Effectiveness (SMART-A)

Bipolar Disorder

Korea, Republic of
H. Lundbeck A/S
Otsuka Pharmaceutical Co., Ltd.

Terminated

Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder

Major Depressive Disorder

United States
UCB Pharma

Completed

The Use of Rotigotine for Treatment of Reducing Signs and Symptoms of Fibromyalgia in Adults. (SP888)

Fibromyalgia Syndrome

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-Term Extension Trial From Late Phase II of SPM 962 in Patients With Restless Legs Syndrome (RLS)

Idiopathic Restless Legs Syndrome
UCB BIOSCIENCES GmbH
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease

Advanced Idiopathic Parkinson's Disease

Korea, Republic of, United States, Malaysia, Singapore, Taiwan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Dose-ranging Study for SPM 962 in Parkinson's Disease Patients

Parkinson's Disease

Japan
Bausch Health Americas, Inc.

No longer available

Compassionate Use Study of Pergolide in Patients With Parkinson's Disease

Parkinson Disease
UCB Pharma

Completed

Study to Compare Adhesiveness of Two Different Rotigotine Patch Formulations

Parkinson's Disease

Germany, Austria, United Kingdom
Ain Shams University
Future University in Egypt

Completed

The Effect of Prucalopride on Gastric Emptying in Intensive Care Unit Patients

Enteral Feeding Intolerance

Egypt
SocraTec R&D GmbH
Luye Pharma Group Ltd.; SocraMetrics GmbH

Completed

Clinical Trial to Investigate Patch Adhesion of Rotigotine Containing Patches in Patients With Parkinson's Disease

Parkinson Disease

Germany
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders

ADHD | Conduct Disorder | Oppositional Defiant Disorder | Autism | Bipolar I Disorder

United States
Luye Pharma Group Ltd.

Completed

Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease

Parkinson's Disease

United States
UCB Pharma

Completed

Named Patient Program With Rotigotine Transdermal System

Conditions for Which There is a Documented Medical Necessity to Receive Treatment With Rotigotine

United States
UCB Pharma

Completed

Non-interventional Study (NIS) in Patients With Restless Legs Syndrome in Daily Practise (RLS-Practise)

Idiopathic Restless Legs Syndrome

Germany
Otsuka Beijing Research Institute

Terminated

The Safety and Efficacy of Brexpiprazole as Adjunctive Therapy in the Treatment of Major Depressive Disorder

Major Depressive Disorder

China
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder.

Bipolar I Disorder | Acute Mania

United States, Serbia, Bulgaria, Croatia, Poland, Ukraine

Search clinical trials for: Dopamine Agonists

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ireland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations